Most likely, additional genes (such as the frequently mutated CDNK2A and SMAD4 genes [8]) or biomarkers associated with pancreatic malignancies (such as DNA methylation [41] and telomerase activity [42]) must be included to fully exploit the clinical potential of pancreatic juice samples in early cancer detection. The gene discussed is SMAD4; the disease is cancer.